Niklas ReichPhD student
PhD Project: 'Development of a Tau aggregation inhibitor peptide and peptide-liposomes as a potential treatment for Alzheimer's Disease'.
My research focuses on the development and testing of our lead Tau aggregation inhibitor peptide ('RI-AG03') as well as peptide-linked liposomes in various Tau cell models and in a P301S Tau transgenic mouse model. To facilitate testing, I have successfully selected a monoclonal, Doxycycline-inducible and 2N4R (full length) Tau-expressing SH-SY5Y cell line during my first year of studies.
I am also involved in the Defying Dementia campaign, which supports those in need and raises funds to maintain our dementia research. For more information, please see: Defying Dementia | Lancaster University
For more information, please feel free to contact me via email or LinkedIn.